Early cancer detection company Grail announced the start of a study to assess the clinical impact of the company’s Galleri multi-cancer early detection test among Medicare beneficiaries, with a specific focus on racial and ethnic minorities in historically underserved communities. The Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity…

Liquid biopsy pioneer GRAIL is a step closer to developing a single blood test to find cancer early.  The company’s candidate blood test detected a strong signal for 12 cancer types at stages I-III, according to results which will be presented today at the American Society of Clinical Oncology (ASCO)…

Freenome has announced $254M of new funding, led by Roche but with multiple other firms participating, to advance the company’s pipeline of single- and multiple-cancer early detection tests built on a multiomics platform. The company’s lead programs are for colorectal and lung cancer screening.  The early cancer detection market is…

New research shows that the adoption of a Lung Nodule Program (LNP) can significantly enhance the detection of early lung cancer among individuals not meeting the age eligibility criteria for traditional lung cancer screening. LNPs are often set up as a way to follow up with patients when lung nodules…

Genomics pioneer Dennis Lo and Prenetics are collaborating to create a new company focused on early cancer detection. The firm, Insighta, will use the breakthrough FRAGMA technology Lo published on in 2022. Prenetics will provide $80M in cash and $20M in stock for the 50/50 joint venture, which, according to…

A blood test based on RNA and AI delivered 87% sensitivity and 95% specificity of detection across eight cancer types, according to results Exai Bio presented in a poster session at ASCO last weekend. This is an important new aspect to the highly competitive multi-cancer early detection (MCED) market. Most…

Mercy BioAnalytics, the developer of an early cancer detection liquid biopsy leveraging extracellular vesicles, has closed a $41 million Series A financing round that will be used to further the development of the company’s novel Mercy Halo test for high-risk lung cancer screening. The financing was led by Novalis LifeSciences,…

Research led by Dr. Raymond Osarogiagbon, chief scientist for Baptist Memorial Health Care that used incidental lung nodule detection was shown to be effective in detecting lung cancer early. The finding, published in JAMA Network Open, support a two-pronged approach that also includes current lung cancer screening guidelines. “This is…

Delfi Diagnostics, which is developing novel liquid biopsy screening tests for cancer leveraging machine learning and genome-wide fragmentation profiles of cell free DNA, announced today that it has closed a $250 million Series B financing round led by DFJ Growth. The new infusion of capital will be used to fund…

Exact Sciences announced it will collaborate with Philadelphia-area with Jefferson Health to conduct research on a new blood-based, multi-cancer earlier detection (MCED) test. The research will engage patients from diverse populations, with the help of primary care and specialty providers and care coordinators to gather information to evaluate methods of…

Caris Life Sciences says the eye-popping $890 million growth equity round it completed this week will enable it to support the commercialization and launch of its early detection blood-based pan-cancer test. The financing, Caris says, will give it the capital needed for bringing to market a first-in-class liquid biopsy platform…

Early and Recurrent Cancer Detection Read Magazine Now

REGISTER NOW Broadcast Date: April 22, 2021Time: 2:00 pm PT, 5:00 pm ET Molecular residual disease (MRD) detection is emerging as a powerful and non-invasive tool for improving the management of cancer in the post-operative treatment setting. Using circulating tumor DNA can help accurately identify MRD sooner than current standard…

Breast cancer early detection could be more practical thanks to a new test being developed by the Translational Genomics Research Institute (TGEN), an Arizona-based  affiliate of California’s City of Hope medical center.  The test can detect very small amounts of extracellular matrix (ECM) cells signaling cancer. The study’s senior author…

Guardant Health will launch its first blood-based liquid biopsy for residual disease detection and recurrence monitoring next month—while later this year it will commercialize its first next-generation tissue-based test, as the diagnostics developer expands its focus beyond late-stage cancer and blood-based tests. The new liquid biopsy, Guardant Reveal, is a…